Beilu Pharmaceutical Raises Funds For CT Contrast Agents
This article was originally published in PharmAsia News
Executive Summary
Beijing Beilu Pharmaceutical has completed issuing 12.5 million additional shares to seven investors and raised RMB 66.625 million. The funds will be invested in the firm's CT contrast agents iopamidol and iodixanol injections to strengthen both products' leading position domestically as well as compete with MNCs. Currently, China's iopamidol market is exclusively monopolized by Italian firm Bracco's local joint venture product Isovue, but Beilu believes that there is still room for growth. GE's imported Visipaque represents the only iodixanol available in the country but its patent protection will expire in June 2010. Beilu aims to develop the iodixanol sector to expand its economic and social benefits in China. (Click here for more - Chinese Language)